WALTHAM, Mass.--(BUSINESS WIRE)--March 6, 2006--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today reported financial results for the fourth quarter and fiscal year ended December 31, 2005. During the fourth quarter of 2005, Oscient recorded $8.0 million in revenue from the Company’s lead product, FACTIVE(R) (gemifloxacin mesylate) tablets, FDA-approved for the treatment of acute bacterial exacerbations of chronic bronchitis (AECB) and mild to moderate community-acquired pneumonia (CAP). Oscient also recorded more than $1.4 million in revenue from the Company’s co-promotion agreement with Auxilium Pharmaceuticals for TESTIM(R) 1% testosterone gel. Total revenues for the fourth quarter of 2005 were $9,487,000; in comparison, revenues for the fourth quarter of 2004 totaled $2,721,000.
